OR WAIT null SECS
June 20, 2024
Imfinzi (durvalumab) combined with chemotherapy decreased the risk of disease progression or death by 58% in a 700-patient trial.
The companies have completed the expansion and qualification phase and now enter a stand-by phase for five years.
June 19, 2024
The $58 million investment has resulted in a 72,000-square-foot facility with a dedicated LC–MS space and molecular suites and will bring as many as 350 new jobs onto the campus.
PRAC is reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.
June 18, 2024
Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.
The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.
Nadia Sellami, PhD, global segment lead for gene and cell therapy at PacBio, talks about long-read sequencing for cell and gene editing in a video interview.
June 17, 2024
Gabi Hanna, MD, CEO and co-founder of Lamassu Pharma talks about a novel oncology platform and the link between science and patient care.
June 14, 2024
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.
Ecolab Life Sciences and Repligen have launched a new affinity resin, DurA Cycle, for large-scale biologics manufacturing.